Czech Academy institute specializing in cancer nucleotide metabolism and molecular biophysics, with single-cell transcriptomics and drug discovery capabilities.
IBT (Institute of Biotechnology, Czech Academy of Sciences) is a research institute specializing in molecular biophysics and cancer biology. Their work spans high-resolution characterization of biomolecules — using advanced spectroscopy, thermodynamics, and single-molecule techniques — through to investigating how cancer cells rewire their nucleotide metabolism. In the MOSBRI infrastructure network they provided access to molecular-scale biophysics methods relevant to drug discovery and biologics development. In their own coordinated project MetaCross, they are dissecting how nucleotide biosynthesis pathways interact in cancer cells using single-cell transcriptomics, targeting a poorly understood vulnerability in tumor metabolism.
In MOSBRI (2021–2025), IBT contributed as a node in a pan-European molecular-scale biophysics infrastructure, offering advanced spectroscopies, hydrodynamics, thermodynamics, and real-time kinetics measurements.
As coordinator of MetaCross (2022–2026), IBT leads research into crosstalk between nucleotide metabolism pathways in cancer cells, using single-cell transcriptomics to resolve metabolic heterogeneity.
Both projects rely on high-resolution single-entity methods: single-molecule biophysics in MOSBRI and single-cell transcriptomics in MetaCross, indicating deep methodological expertise at this scale.
MOSBRI explicitly targets drug discovery and biologics as application domains, suggesting IBT's biophysics capabilities are positioned toward pharmaceutical research workflows.
MetaCross keywords include 'de novo synthesis', pointing to a specific and technically demanding focus on biosynthetic pathway reconstruction in cancer — an emerging niche.
IBT entered H2020 with a strong footing in physical biochemistry — precise biophysical measurement of molecules in solution using spectroscopy, calorimetry, hydrodynamics, and real-time kinetics, with relevance to drug discovery and biologics. By their second project (2022), the focus had pivoted toward cell-level cancer biology: the same rigor now applied to metabolic pathways inside individual cancer cells, with single-cell transcriptomics as the key readout. The trajectory is a clear shift from characterizing purified molecules toward understanding metabolic dysfunction in disease contexts, suggesting IBT is moving from enabling-technology provider toward a more disease-focused research identity.
IBT is moving from physical characterization of biomolecules toward mechanistic cancer biology, making them an increasingly relevant partner for oncology-focused consortia needing single-cell or metabolomics expertise.
IBT operates in both leader and partner roles, which is notable for a two-project portfolio — they coordinate MetaCross independently while also embedding within the larger MOSBRI infrastructure consortium. Their network of 17 partners across 10 countries suggests they engage in genuinely international consortia rather than staying within a tight national circle. The willingness to coordinate a focused mechanistic project while simultaneously participating in a broader infrastructure network indicates flexibility in how they engage with collaborators.
IBT has built connections with 17 unique partner organizations spanning 10 countries through just two projects, reflecting the broad consortium structures typical of both infrastructure (MOSBRI) and Research and Innovation Actions. Their geographic spread suggests European-level integration rather than a purely regional or national collaboration pattern.
IBT sits at an unusual intersection: a biophysics-grade measurement institute that has pivoted into cancer metabolism research, giving them both the analytical precision of a structural biology facility and the disease relevance of a biomedical research group. This dual capability — characterizing molecules at the single-molecule level AND mapping metabolic states at the single-cell level — is rare and valuable for consortia that need both rigorous biophysical grounding and translational oncology relevance. For a consortium builder, IBT offers a credible Czech Academy node with a clear scientific niche rather than a generalist profile.
